SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2806

Change

0.00 (0.00)%

Market Cap

N/A

Volume

33.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 239.31B
AMGN Amgen Inc

N/A

USD 167.62B
SNY Sanofi ADR

N/A

USD 125.21B
GILD Gilead Sciences Inc

N/A

USD 82.18B
BIIB Biogen Inc

N/A

USD 33.03B
GRFS Grifols SA ADR

N/A

USD 6.07B
AMRN Amarin Corporation PLC

N/A

USD 0.36B
SCLX Scilex Holding Company

N/A

USD 0.10B
MIRA MIRA Pharmaceuticals Inc. Comm..

N/A

USD 0.02B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.06% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.06% 40% F 23% F
Trailing 12 Months  
Capital Gain -81.04% 22% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.04% 22% F 7% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.80% 44% F 28% F
Dividend Return -8.80% 44% F 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.59% 22% F 38% F
Risk Adjusted Return -19.74% 44% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector